The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I’ll simplify it:
100% of the professional panel voted to buy NCYT
Separately - the 300 audience voted.
13% voted to sell or avoid NCYT (probably AVCT / ODX holders).
That leaves 87% as a buy / hold.
Mello / Stockopedia Investor Event
Fantastic for NCYT with 100% of the judging panel and 87% of the 300 investor audience recommending buy or hold.
Not so good for ODX - see poll on twitter - might see some switching over to NCYT this week.
https://twitter.com/blad3sharp/status/1318293454745722890?s=10
As I keep repeating the broker note is so low (£13.60 short term) £34 longer term because it is based on £150 million contract from the Gov 2 weeks ago.
We know this is in fact £469 million from the Bidstats website. (The broker hasn’t used this figure as NCYT hasn’t RNSed the larger amount - the RNS stated MINIMUM £150 million - which cover £469 million.)
The researched know how understated GM is.
So the broker note is 3 times undervalued IMO currently.
Tests (both antigen and antibody will be needed for years alongside a vaccine.
They are HOPING for 50% efficacy with the vaccine and many people saying they won’t take one anyway.
Unfortunately the virus will be here for years even once worldwide vaccines are rolled out.
We need to control it in the meantime by testing and isolation.
I think once institutions and high net worth investors with access to much better research are properly onboard vaccines coming out won’t that much impact as people realise testing is still needed alongside vaccines and NCYT is much more than Covid19 anyway.
Massively undervalued under £20 - should be over £35 minimum next year
I think once institutions and high net worth investors with access to much better research are properly onboard vaccines coming out won’t have a massive impact as people realise testing is still needed alongside vaccines and NCYT is much more than Covid19 anyway.
Massively undervalued under £20 - should be over £35 minimum next year
https://www.sharebuyers.co.uk/shares/numis-broker-note-says-novacyt-share-price-could-quadruple/
Numis broker note says Novacyt shares could quadruple and achieve mid-cap status.
Sharebuyers.co.uk
October 17, 2020. ShareBuyers
The share price of Novacyt could quadruple in value to £34 according to estimates put forward by its broker Numis.
After initiating coverage, Novacyt issued a broker note on Friday morning that heralded a ‘new diagnostics leader emerges’.
At the time of writing the share price of Novacyt was at £8.35 – however it later climbed by over 10% following the report which initiated a buy recommendation on the share with a target price of £13.65.
However, the valuation of £13.65 is conservative even by Numis’s own admissions. It notes that this is somewhere between its base and bull case forecast between £9.5 and £15.
Its most bullish forecast could see Novacyt hit £34 a share considering its longer-term potential and recurring revenues into the NHS, contributing to a peak of 1bn EURO in revenue in the long-term.
This would essentially quadruple the value of the shares and firmly cement its status as a mid-cap company (with a £2bn+ m.cap) as CEO Graham Mullis previously outlined to Sharebuyers.
Breaking down its rationale into four areas, Numis highlighted the following points:
First mover advantage which has allowed it to rapidly scale up its business.
A stronger H2 and 2021 with revenues expected forecast anywhere from 380m EUR to over 600m EUR.
Strong cash generation and acquisitions means it will be able to consolidate the wider diagnostics industry.
Longer-term potential as discussed above.
Our view on Numis’s outlook for Novacyt
This is not just another positive broker note. It mirrors what we have been saying about Novacyt for quite some time and all adds up.
If anything, its current target price appears to be quite conservative and it focuses mainly on NHS revenues. Numis themselves noted that its target price is on the low side considering the long-term potential.
At the moment, the market still hasn’t quite grasped the earnings prowess of Novacyt but soon it won’t be able to ignore the quite frankly sky-high numbers it will be posting.
Novacyt is a phenomenal AIM and business growth success story which has a few more chapters left in it.
Hold for gold!
Yes - been emailing GM for months so built up some trust but he never says anything that hasn’t been RNSed.
Good to hear his confidence though.
This is literally the biggest no brainer investment risk / reward I’ve ever come across in over 20 years.
Been saying this since £1.50 - people finally starting to understand.
Personal target £30 - £60 next year.
It’s not fake - I emailed GM yesterday congratulating him on the acquisition and broker note and he replied saying it’s much appreciated.
Unless GM is fake then the broker note isn’t.
Very conservative Broker note - saying revenues expected to be over £300 million when the fully researched know it’s already over £500 million probably over £600 million with recent Government contracts.
More contracts due very shortly.
Just a theory but if no major news tomorrow I reckon GM will release it Monday / Tuesday so as not seen to be taking advantage of his bonus day....
Definitely wouldn’t want to be out over the weekend!!
Care Home contract imminent
French tender imminent
Broker update imminent
Head of vaccine development just been on Radio 5.
They are hoping for 50% efficacy - same as the flu vaccine.
Meaning it will only be successful to prevent Covid19 in 50% of people.
Testing here to stay a very long time.